- Home
- RCKT vs FBRX Comparison
RCKT vs FBRX Comparison
Compare RCKT & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCKT | FBRX |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.6M | 367.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RCKT | FBRX |
|---|---|---|
| Price | $3.65 | $33.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | $29.12 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 1.9M | 207.4K |
| Earning Date | 02-26-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.19 | $4.90 |
| 52 Week High | $11.45 | $34.19 |
Technical Indicators
Market Signals| Indicator | RCKT | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.98 | 69.08 |
| Support Level | $3.47 | $23.11 |
| Resistance Level | $3.98 | $34.19 |
| Average True Range (ATR) | 0.23 | 3.40 |
| MACD | 0.01 | 0.59 |
| Stochastic Oscillator | 44.93 | 96.51 |
Price Performance
Historical ComparisonAbout RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).